French Drug Contract Tester Warned for GMP Violations

March 19, 2018

The FDA warned a French drug contract testing laboratory following a September inspection that revealed deficiencies in testing practices and discrepancy investigations.

The agency said Quali-Controle & Quali-Controle C.E.BAC used non validated test methods to assess its customers’ drug products. The firm’s inadequate response was to add a comment to its certificate of analysis to say it used non-validated test methods.

In addition, the firm’s atomic absorption analysis of a sample and its retest were both out-of-specification, and were invalidated without justification or inquiry. The company said dirty glassware in prior tests and preparations caused the failures, and that it resolved the problem by cleaning them.

View today's stories